NCT05342948 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Kolte AM, Steffensen R, Christiansen OB, Nielsen HS
Maternal HY-restricting HLA class II alleles are associated with poor long-term outcome in recurrent pregnancy loss after a boy. Am J Reprod Immunol. 2016 Nov;76(5):400-405. doi: 10.1111/aji.12561. Epub 2016 Sep 7.
Nielsen HS, Steffensen R, Varming K, Van Halteren AG, Spierings E, Ryder LP, Goulmy E, Christiansen OB
Association of HY-restricting HLA class II alleles with pregnancy outcome in patients with recurrent miscarriage subsequent to a firstborn boy. Hum Mol Genet. 2009 May 1;18(9):1684-91. doi: 10.1093/hmg/ddp077. Epub 2009 Feb 17.

Pregnancy Outcome After Secondary Recurrent Pregnancy Loss (sRPL) is Influenced by Sex of the First Born Child and Maternal Carriage of HY-restricting HLA Class II Alleles

Details for clinical trial NCT05342948

Clinical trial NCT05342948 - References